{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":10,"description":"New diagnosis, high risk smoldering MM, relapse as defined by investigator. Participants received 4 different techniques of diagnosis: Fludeoxyglucose (F-18 FDG) PET/MRI, Sodium Acetate (C-11 acetate) PET/CT, C-11 PET/MRI, and F-18 FDG PET/CT. Each participant received both PET drugs by both diagnostic techniques and is therefore included in the analysis population for the four reporting groups.\n\nFludeoxyglucose: Route of administration was intravenous. Dose of each injection was the standard 5 to 10 millicurie (mCi).\n\nSodium Acetate C11: Route of administration was intravenous. Dose of each injection was 10 mCi (370 MBq).","id":"EG000","otherNumAffected":0,"otherNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"title":"Multiple Myeloma (MM) Patients"}],"frequencyThreshold":"0","timeFrame":"Adverse Events were collected from baseline to one day following the last administration of study treatment, for at total of approximately 3 days."}